Literature DB >> 34611868

Rapid Antibody Glycoengineering in CHO Cells Via RNA Interference and CGE-LIF N-Glycomics.

Pavlos Kotidis1, Masue Marbiah1,2, Roberto Donini1,3, Itzcóatl A Gómez4, Ioscani Jimenez Del Val4, Stuart M Haslam3, Karen M Polizzi1,2, Cleo Kontoravdi5.   

Abstract

The impact of the glycan distribution on the in vivo function and half-life of monoclonal antibodies has long motivated the genetic engineering of producer cells to achieve structures that enhance efficacy, safety and stability. To facilitate glycoengineering of IgG-producing Chinese hamster ovary cells, we present a rapid protocol that involves the use of RNA interference for the knockdown of genes of interest coupled with capillary gel electrophoresis and laser-induced fluorescence detection (CGE-LIF) for fast, high-throughput glycan analysis. We apply this methodology to the Fut8 gene, responsible for the addition of core fucose, which is a typical target for increasing antibody-dependent cellular cytotoxicity.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antibody-dependent cell cytotoxicity; Capillary gel electrophoresis; Chinese hamster ovary cells; Fucosylation; Gene knockdown; RNAi; siRNA

Mesh:

Substances:

Year:  2022        PMID: 34611868     DOI: 10.1007/978-1-0716-1685-7_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  90 in total

Review 1.  Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.

Authors:  Liming Liu
Journal:  J Pharm Sci       Date:  2015-04-14       Impact factor: 3.534

2.  Quality by design for biopharmaceuticals.

Authors:  Anurag S Rathore; Helen Winkle
Journal:  Nat Biotechnol       Date:  2009-01       Impact factor: 54.908

3.  Biopharmaceutical benchmarks 2018.

Authors:  Gary Walsh
Journal:  Nat Biotechnol       Date:  2018-12-06       Impact factor: 54.908

4.  Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Authors:  R A Clynes; T L Towers; L G Presta; J V Ravetch
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

5.  Fc receptors are required in passive and active immunity to melanoma.

Authors:  R Clynes; Y Takechi; Y Moroi; A Houghton; J V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

Review 6.  Advances in the production of human therapeutic proteins in yeasts and filamentous fungi.

Authors:  Tillman U Gerngross
Journal:  Nat Biotechnol       Date:  2004-11       Impact factor: 54.908

7.  Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.

Authors:  Shigeru Iida; Hirofumi Misaka; Miho Inoue; Mami Shibata; Ryosuke Nakano; Naoko Yamane-Ohnuki; Masako Wakitani; Keiichi Yano; Kenya Shitara; Mitsuo Satoh
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

8.  Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.

Authors:  Asahi Ito; Takashi Ishida; Hiroki Yano; Atsushi Inagaki; Susumu Suzuki; Fumihiko Sato; Hisashi Takino; Fumiko Mori; Masaki Ri; Shigeru Kusumoto; Hirokazu Komatsu; Shinsuke Iida; Hiroshi Inagaki; Ryuzo Ueda
Journal:  Cancer Immunol Immunother       Date:  2008-12-02       Impact factor: 6.968

Review 9.  Glycosylation as a strategy to improve antibody-based therapeutics.

Authors:  Roy Jefferis
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

10.  Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies.

Authors:  Xiaojie Yu; Kavitha Baruah; David J Harvey; Snezana Vasiljevic; Dominic S Alonzi; Byeong-Doo Song; Matthew K Higgins; Thomas A Bowden; Christopher N Scanlan; Max Crispin
Journal:  J Am Chem Soc       Date:  2013-06-25       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.